Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Sierra Natl BK Tehachapi Calif (MM) Charts. Click Here for more Sierra Natl BK Tehachapi Calif (MM) Charts.](/p.php?pid=staticchart&s=N%5ESIRT&p=8&t=15)
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs to
treat diseases of aging, announced today that it presented data from
pre-clinical and Phase 1a studies at the 6th Annual Metabolic Diseases
Drug Discovery and Development World Summit in San Diego, California on
July 17, 2007. As previously announced, Jill Milne, Ph.D., Senior
Director of Biology at Sirtris, delivered a keynote address “SIRT1
Activation: A Novel Mechanism for Treating Type 2 Diabetes.”
Dr. Milne presented data which showed that SRT501, Sirtris' proprietary
formulation of resveratrol, reduces glucose and improves insulin
sensitivity in multiple pre-clinical models of Type 2 Diabetes. Dr.
Milne also presented pharmacokinetic (PK) data from a Phase 1a study
conducted by Sirtris in which healthy volunteers who were dosed with
SRT501 had an improved exposure as compared with other published
studies. Both the area under the curve concentrations (AUC) as well as
the maximal concentrations (Cmax) were shown to be improved with SRT501
as compared with literature values for resveratrol. SRT501 is currently
being tested in a Phase 1b study in patients with Type 2 Diabetes.
Furthermore, Dr. Milne presented data with certain Sirtris proprietary
novel chemical SIRT1 activators, structurally unrelated to resveratrol,
which were shown to reduce glucose, improve insulin sensitivity, improve
glucose tolerance, and increase the number and function of mitochondria
in multiple pre-clinical models of Type 2 Diabetes. In addition, studies
in a pre-clinical model demonstrate improved insulin sensitivity in
muscle, liver, and fat cells.
“Sirtris scientists continue to make
significant progress in the development of SIRT1 activators for diseases
of aging such as Type 2 Diabetes. Indeed, the new data presented today
further extend Sirtris’ scientific leadership
in advancing sirtuin modulators as a new class of innovative
therapeutics,” said Christoph Westphal, M.D.,
Ph.D., Chief Executive Officer of Sirtris.
About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company focused on
discovering and developing proprietary, orally available, small molecule
drugs with the potential to treat diseases associated with aging,
including metabolic diseases such as Type 2 Diabetes. Our drug
candidates are designed to mimic certain beneficial health effects of
calorie restriction, without requiring a change in eating habits, by
activation of sirtuins, a recently discovered class of enzymes that
control the aging process. The company's headquarters are in Cambridge,
Massachusetts.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
statements include, but are not limited to, the progress of pre-clinical
and clinical studies of SIRT1 activators, the results of pre-clinical
studies as compared with other published studies, Sirtris’
position in the sirtuin field, and the potential for sirtuin modulators
to receive regulatory approval. These forward-looking statements about
future expectations, plans and prospects of Sirtris Pharmaceuticals
involve significant risks, uncertainties and assumptions, including
risks related to the lack of results that would provide a basis for
predicting whether any of the Company’s
product candidates will be safe or effective, or receive regulatory
approval, the possibility that results of pre-clinical studies are not
necessarily predictive of clinical trial results, the Company's
potential inability to initiate and complete pre-clinical studies and
clinical trials for its product candidates, the fact that none of the
Company's product candidates has received regulatory approvals, the
potential inability of the Company to gain market acceptance of the
Company's product candidates, and those other risks factors that can be
found in the Company's filings with the Securities and Exchange
Commission. Actual results may differ materially from those Sirtris
Pharmaceuticals contemplated by these forward-looking statements.
Sirtris Pharmaceuticals does not undertake to update any of these
forward-looking statements to reflect a change in its views or events or
circumstances that occur after the date of this release.